Gemcitabine and haemolytic-uraemic syndrome [2]

Annals of Oncology

Volumn 15, Issue 10, 2004, Pages 1575-1576

  Ruiz, I ^a   Del Valle, J ^a   Gomez A ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; TEGAFUR;

ADULT; ANGINA PECTORIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CASE REPORT; CORTICOSTEROID THERAPY; DEATH; DYSPNEA; HEART INFARCTION; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN CELL; HYPERTENSION; KIDNEY DYSFUNCTION; LABORATORY TEST; LETTER; LUNG METASTASIS; LYMPHADENOPATHY; MALE; PANCREAS CARCINOMA; PANCREATICODUODENECTOMY; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT PLANNING;

EID: 6944226234     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh397     Document Type: Letter

References (5)

1. Walter RB, Joerger M, Pestalozzi BC. Gemcitabine associated haemolytic uremic syndrome. Am J Kidney Dis 2002; 40(4): E16.
2. Casper ES, Green MR, Kelsen DP et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12: 29-34.
3. Flombaum CD, Mouradiau JA, Casper ES et al. Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine. Am J Kidney Dis 1999; 33: 555-563.
4. Dilhuydy MS, Delclaux C, Pariente A et al. Syndrome hémolytique et urémique compliquant un traitemente au long cours par gemcitabine. Rev Med Interne 2002; 23: 189-192.
5. Fung MC, Storniolo AM, Nguyen B et al. A review of hemolytic, uremic syndrome in patients treated with gemcitabine therapy. Cancer 1999; 85: 2023-2031.